Mezzion Pharma Sells Australian Udenafil Patents for USD 4 Million
Mezzion Pharma sold its Australian udenafil patents to Hepaguard for USD 4 million.
Related stories
Exel Composites Q3 adjusted operating profit more than triples
M impact | EQUITY | Nov 04, 2026, 06:18 AM UTC
Siltronic Widens Q1–Q3 2026 Net Loss Year Over Year
Siltronic raised its FY26 revenue forecast to the prior-year level.
M impact | EQUITY | Nov 04, 2026, 06:08 AM UTC
Pion Group Operating Profit More Than Triples in Q3
M impact | EQUITY | Nov 04, 2026, 06:06 AM UTC
Pion Group Q3 Operating Profit More Than Triples; Revenue Rises
Pion Group said Q3 operating profit more than tripled, while revenue also increased.
M impact | EQUITY | Nov 04, 2026, 06:06 AM UTC
Exel Composites Q3 Adjusted Operating Profit More Than Triples to EUR 3.38 Million
M impact | EQUITY | Nov 04, 2026, 06:06 AM UTC
Solstad Maritime narrows full-year adjusted EBITDA guidance to USD 375 -390 MLN
M impact | EARNINGS | Nov 04, 2026, 06:06 AM UTC